A Vitamin Deficiency With a Route Question Nobody Settled
A single patient with a textbook diagnosis and an old teaching about its treatment that the actual absorption physiology no longer fully supports. The disagreement is about whether her existing neurologic symptoms change what counts as an adequate substitute for the shortcut oral therapy usually offers.
L.G., a 59-year-old retired librarian, spent nearly a year attributing her fatigue and tingling fingertips to "just getting older" before a routine CBC finally flagged a macrocytic anemia severe enough that her primary care physician wouldn't let it wait. Workup confirmed autoimmune atrophic gastritis — parietal cell and intrinsic factor antibodies both positive, gastric biopsy showing the characteristic corpus-predominant atrophy — the classic cause of pernicious anemia, where the stomach's own immune-mediated destruction of parietal cells eliminates the intrinsic factor B12 absorption depends on.
The reflex teaching for pernicious anemia is intramuscular B12 injections, bypassing the gut entirely on the assumption that oral B12 is useless without intrinsic factor — but that assumption oversimplifies the actual absorption physiology. A separate, intrinsic-factor-independent pathway exists: roughly 1% of an oral B12 dose is absorbed by passive diffusion across the intestinal mucosa regardless of intrinsic factor status, meaning oral doses in the 1000 to 2000 microgram range can deliver a therapeutic amount even in her setting, and Kuzminski and colleagues' 1998 randomized comparison found hematologic and neurologic correction on 2000mcg daily oral cobalamin prompt and indistinguishable from a standard intramuscular schedule. The trial is also smaller than its reputation suggests — folate deficiency knocked out enough participants to leave 18 evaluable patients taking oral therapy and 15 on injections, which is a thin base from which to read anything about a subgroup.
The second thread in her workup matters just as much long-term: chronic loss of parietal cell acid output removes normal feedback inhibition on gastrin secretion, driving chronic hypergastrinemia that can, over years, stimulate enterochromaffin-like cell hyperplasia in the gastric body — the precursor lesion for type 1 gastric neuroendocrine tumors, a real and specific reason her gastritis needs ongoing endoscopic surveillance, not just a vitamin prescription and a one-time referral. Type 1 gastric NETs are, reassuringly, typically small, multiple, and indolent — rarely metastatic — but the surveillance interval itself (most society guidance favors endoscopy roughly every one to two years) is a real, ongoing commitment distinct from and outlasting whatever B12 route she and her team settle on today.
When "equivalent" isn't the only variable that matters
The old teaching that oral B12 is useless without intrinsic factor doesn't hold up against the actual absorption physiology — about 1% of an oral dose crosses the gut by passive diffusion regardless of intrinsic factor status, and at a dose of 1000 to 2000 micrograms daily, that 1% is still a therapeutic amount.
Kuzminski and colleagues' randomized comparison found hematologic and neurologic correction on daily high-dose oral cobalamin indistinguishable from intramuscular dosing. Given she'd clearly rather avoid recurring injections, I'd start oral.
I don't dispute the equivalence data in general — they're real, and for most patients I'd agree oral is a fine starting point.
What gives me pause is that she isn't just lab-abnormal, she has active neurologic findings already — fingertip paresthesias and reduced vibratory sense. Neurologic B12 deficiency doesn't always fully reverse if correction is slow, and while oral absorption is adequate on average, it's also more variable day to day than a loading injection gives you. I'd rather load her with IM B12 first, where the correction curve is faster and more predictable, and switch to oral once her neurologic findings are clearly moving in the right direction.
That's a fair distinction, and the numbers are on your side of it — Kuzminski's oral arm came down to eighteen evaluable patients, which is nowhere near enough to tell us how the handful with neurologic findings did. I'd rather not extrapolate past what that actually tested. I'll defer to IM loading given her current exam findings, with oral high-dose therapy as the maintenance plan once we've confirmed real neurologic improvement, which does give her the lower-burden long-term option she'd prefer.
IM B12 loading started given her active neurologic findings, with an explicit plan to transition to high-dose oral maintenance once hemoglobin, MCV, and neurologic exam findings clearly improve — and endoscopic surveillance for type 1 gastric neuroendocrine tumors scheduled separately, given her chronic hypergastrinemia.
Agreed cleanly: the Clinical Pharmacologist's route argument wasn't wrong about the pharmacology, only incomplete for a patient whose neurologic findings changed what "equivalent" needed to account for — both physicians treated the oral evidence as real and relevant to her eventual maintenance plan, not discarded.